SCHEMBL1833271

SCHEMBL1833271

Cc1cncc(CC(=O)N2CCCC(Nc3ncnc4c3cnn4-c3ccc(S(C)(=O)=O)cc3)C2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.55
TP53 P04637 12/20 0.50
LMNA P02545 3/20 0.50
ALDH1A1 P00352 3/20 0.47
HSD17B10 Q99714 3/20 0.47
NPC1 O15118 2/20 0.47
HPGD P15428 2/20 0.47
RAB9A P51151 2/20 0.47
PIK3CD O00329 2/20 0.47
KDM4E B2RXH2 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 2/20 0.46
PIK3CA P42336 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL388772 0.88 GPR119 (0.57) GPR119TP53LMNAALDH1A1HSD17B10
SCHEMBL389381 0.81 GPR119 (0.59) GPR119TP53LMNAALDH1A1HSD17B10
SCHEMBL388470 0.81 GPR119 (0.58) GPR119TP53LMNAALDH1A1HSD17B10
SCHEMBL390957 0.80 GPR119 (0.82) GPR119TP53LMNAALDH1A1HSD17B10
SCHEMBL389222 0.79 GPR119 (0.58) GPR119TP53LMNAALDH1A1HSD17B10
SCHEMBL1833273 0.79 TP53 (0.50) GPR119TP53LMNAALDH1A1HSD17B10
SCHEMBL389412 0.78 GPR119 (0.58) GPR119TP53LMNAALDH1A1HSD17B10
SCHEMBL12914919 0.77 TP53 (0.74) GPR119TP53LMNAALDH1A1HSD17B10
SCHEMBL391160 0.75 GPR119 (0.91) GPR119ALDH1A1HSD17B10NPC1HPGD
SCHEMBL1244863 0.74 GPR119 (0.60) GPR119TP53LMNAALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2322150-A2 Method of identifying GLP-1 secretagogues Arena Pharmaceuticals, Inc. (US) 2011-05-18 EP disclosed
EP-2322157-A1 Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level Arena Pharmaceuticals, Inc. (US) 2011-05-18 EP disclosed
EP-2322151-A2 Sustained release formulation comprising a GPR119 agonist and a DPP-IV inhibitor Arena Pharmaceuticals, Inc. (US) 2011-05-18 EP disclosed